Narrative Update • Jun 26
Have your own idea? Try our Stock Screener
U.K. (FTSE) Clinical Research and Equipment Industry Analysis
UpdatedJun 30, 2026
DataAggregated Company Financials
Companies7
- 7D5.8%
- 3M8.4%
- 1Y-9.9%
- YTDn/a
In the last week, the Clinical Research and Equipment industry is up 4.5%, with Oxford Nanopore Technologies up 8.0%. Meanwhile, hVIVO actually underperformed within the industry, shrinking 9.3% in the last week. However, the industry is down 8.1% over the past year. As for the next few years, earnings are expected to grow by 57% per annum.
Industry Valuation and Performance
Has the U.K. Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 30 Jun 2026 | UK£1.4b | UK£323.0m | -UK£166,018,254.00 | 1261.3x | -8.4x | 4.3x |
| Thu, 28 May 2026 | UK£1.6b | UK£323.0m | -UK£166,018,254.00 | 1291.7x | -9.4x | 4.8x |
| Sat, 25 Apr 2026 | UK£1.3b | UK£318.2m | -UK£167,469,254.00 | n/a | -8.1x | 4.2x |
| Mon, 23 Mar 2026 | UK£1.4b | UK£324.0m | -UK£161,423,254.00 | 8.9x | -8.5x | 4.2x |
| Wed, 18 Feb 2026 | UK£1.5b | UK£304.7m | -UK£159,511,254.00 | 11.8x | -9.6x | 5x |
| Fri, 16 Jan 2026 | UK£1.7b | UK£304.6m | -UK£159,441,254.00 | 7.7x | -10.8x | 5.7x |
| Sun, 14 Dec 2025 | UK£1.4b | UK£304.4m | -UK£160,881,254.00 | 6.8x | -8.8x | 4.6x |
| Tue, 11 Nov 2025 | UK£1.6b | UK£304.3m | -UK£163,156,254.00 | 8.1x | -9.5x | 5.1x |
| Thu, 09 Oct 2025 | UK£1.7b | UK£304.3m | -UK£163,156,254.00 | 8.3x | -10.2x | 5.5x |
| Sat, 06 Sep 2025 | UK£1.8b | UK£313.5m | -UK£158,190,352.00 | 6.5x | -11.3x | 5.7x |
| Mon, 04 Aug 2025 | UK£2.1b | UK£291.9m | -UK£160,968,352.00 | 6.4x | -13.3x | 7.3x |
| Wed, 02 Jul 2025 | UK£1.5b | UK£291.9m | -UK£160,968,352.00 | 7x | -9.5x | 5.2x |
| Fri, 30 May 2025 | UK£1.6b | UK£319.5m | -UK£190,907,906.20 | 10.3x | -8.5x | 5.1x |
| Sun, 27 Apr 2025 | UK£1.6b | UK£313.9m | -UK£192,362,214.35 | 10.9x | -8.4x | 5.1x |
| Tue, 25 Mar 2025 | UK£1.5b | UK£315.6m | -UK£186,230,048.15 | 6x | -8x | 4.7x |
| Thu, 20 Feb 2025 | UK£1.8b | UK£306.5m | -UK£195,180,498.48 | 7x | -9.4x | 6x |
| Sat, 18 Jan 2025 | UK£2.1b | UK£307.8m | -UK£196,188,968.40 | 7.1x | -10.5x | 6.7x |
| Mon, 16 Dec 2024 | UK£2.1b | UK£306.4m | -UK£195,163,702.56 | 8.5x | -10.8x | 6.9x |
| Wed, 13 Nov 2024 | UK£1.9b | UK£305.4m | -UK£193,268,388.16 | 11.6x | -10x | 6.4x |
| Fri, 11 Oct 2024 | UK£2.0b | UK£304.5m | -UK£192,368,251.90 | 10.5x | -10.4x | 6.5x |
| Sun, 08 Sep 2024 | UK£2.0b | UK£293.4m | -UK£192,317,721.90 | 12.2x | -10.4x | 6.8x |
| Tue, 06 Aug 2024 | UK£1.8b | UK£295.7m | -UK£190,046,673.15 | 11.9x | -9.3x | 6x |
| Thu, 04 Jul 2024 | UK£1.5b | UK£295.7m | -UK£190,047,404.49 | 11.5x | -8.1x | 5.2x |
| Sat, 01 Jun 2024 | UK£1.6b | UK£295.6m | -UK£189,808,553.55 | 11.3x | -8.6x | 5.5x |
| Mon, 29 Apr 2024 | UK£1.5b | UK£292.9m | -UK£189,020,345.45 | 7254.7x | -7.7x | 5x |
| Wed, 27 Mar 2024 | UK£1.8b | UK£295.9m | -UK£213,220,719.91 | 7353.7x | -8.4x | 6x |
| Fri, 23 Feb 2024 | UK£2.0b | UK£285.8m | -UK£189,230,023.72 | 6965.2x | -10.5x | 7x |
| Sun, 21 Jan 2024 | UK£2.9b | UK£450.2m | -UK£176,590,140.00 | 62.1x | -16.2x | 6.4x |
| Tue, 19 Dec 2023 | UK£3.1b | UK£450.2m | -UK£174,195,438.00 | 52.7x | -17.6x | 6.8x |
| Thu, 16 Nov 2023 | UK£3.0b | UK£455.8m | -UK£168,936,857.00 | 48.6x | -18x | 6.7x |
| Sat, 14 Oct 2023 | UK£2.9b | UK£458.8m | -UK£165,696,571.00 | 51.1x | -17.6x | 6.4x |
| Mon, 11 Sep 2023 | UK£3.1b | UK£440.5m | -UK£166,985,165.00 | 69.6x | -18.6x | 7x |
| Wed, 09 Aug 2023 | UK£3.4b | UK£476.6m | -UK£124,733,230.00 | 70.6x | -27x | 7.1x |
| Fri, 07 Jul 2023 | UK£2.9b | UK£476.6m | -UK£124,749,031.00 | 66.1x | -23.3x | 6.1x |
Price to Earnings Ratio
-23.3x
Current Industry PE
- Investors are pessimistic on the British Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 5.8x is higher than the industry's current PS ratio of 4.4x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have deteriorated over the last three years.
- Revenues have also declined 12% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Comparison
How does U.K. Clinical Research and Equipment compare with similar industries?
| GB Market | 0.17% | |
| Healthcare | 5.87% | |
| Life Sciences | 5.85% | |
| Clinical Research and Equipment | 5.85% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ONT Oxford Nanopore Technologies | UK£1.22 | 8.0% +UK£88.5m | -10.7% | PS5.3x | |
| PRM Proteome Sciences | UK£0.018 | 20.0% +UK£1.1m | -41.0% | PS1.7x | |
| GDR genedrive | UK£0.013 | 2.0% +UK£401.4k | -7.1% | PS17.8x |